A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-Blind, Randomized, Placebo-Controlled
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
Actual Study Start Date: June 6, 2019
Estimated Primary Completion Date: April 30, 2020
Estimated Study Completion Date: May 15, 2020

Arms:
- Experimental: Elobixibat
- Placebo Comparator: Placebo